Preparative and Process Chromatography Market

The global preparative and process chromatography market is projected to reach USD 21.50 billion by 2031, up from USD 14.32 billion in 2026, growing at a CAGR of 8.2% during the forecast period

Vaccines and recombinant proteins using new modalities such as CGT, oligos, and mRNA are expected to increase in volume as demand for more personalized treatments rises in some developed economies. With increased volume, this growing diversity of biologics will need to be purified. These shifts make chromatography a critical unit operation, especially for capture and purification. With quality control reforms, agencies expect tighter control of host-cell proteins, DNA, aggregates, and residual ligands. These macro trends are projected to increase production volume in the bioprocessing niche. This will help drive demand for relevant products used in preparative and process-scale chromatography. These factors will help drive the market for preparative and process chromatography.

To know about the assumptions considered for the study download the pdf brochure

Market growth is driven by increased outsourcing of services by pharmaceutical and biopharmaceutical companies to CDMOs and CROs. Leading companies are expanding multi-plant bio-manufacturing in developed regions. The global monoclonal antibody (mAb) pipeline is growing, as evidenced by numerous FDA approvals and the launch of new bispecific antibodies and antibody-drug conjugates. This trend has increased purification needs among end users, supporting overall demand for columns, resins, and other relevant products for preparative and process chromatography.

The competitive landscape of the preparative and process chromatography market includes several strong multinational companies that capture a significant share of the market. Additionally, some small- to medium-sized enterprises (SMEs) and regional players maintain a noteworthy presence. Major participants in the preparative and process chromatography market include Danaher Corporation (US), Merck KGaA (Germany), Sartorius AG (Germany), Thermo Fisher Scientific (US), and Waters Corporation (US). Other players that have acquired a sizable share in the market include Agilent Technologies, Inc. (US), Bio-Rad Laboratories, Inc. (US), Avantor, Inc. (US), Sartorius AG (Germany), Repligen Corporation (US), Shimadzu Corporation (Japan), Ecolab Inc. (US), Tosoh Bioscience (Japan), Mitsubishi Chemical Group Corporation (Japan), Revvity (US), PerkinElmer (US), Cecil Instruments Limited (UK), W.R. Grace & Co. (US), Ecom SPO (Czech Republic), BUCHI Labortechnik AG (Switzerland), Good Science (Tianjin) Instrument Technologies Co., Ltd. (China), Bio Works Technologies (Sweden), Sykam GmbH (Germany), Sunresin New Materials Co., Ltd. (China), YMC Co., Ltd. (Japan), and Geno Technology Inc. (US).

Danaher Corporation (US)

Danaher Corporation is a US-based company that designs, manufactures, and markets medical, industrial, and commercial products and services. Cytiva (formerly GE Healthcare Life Sciences) is globally recognized as the dominant manufacturer of resins, columns, and solvents. The business employs an aggressive revenue model; the majority of Danaher's revenue is recurring, with chromatography resins and process consumables providing predictable, high-margin cash flows. Danaher's strategic manufacturing expansion, including a planned $1.5 billion capital deployment over two years and a second dedicated resin facility in the US, positions Cytiva to serve global biopharmaceutical customers with proximity and scalable capacity. Integration with Pall creates downstream synergies spanning clarification, viral inactivation, and drug product filtration, addressing the full bioprocessing value chain. Cytiva operates resin manufacturing facilities with redundant capacity, including its Uppsala (Sweden) site, which was specifically built to mitigate supply risk. Cytiva’s products are embedded in countless approved biologics manufacturing processes globally.

Merck KGAA (Germany)

Merck KGaA is another major player in the market. The company is a leading provider of chromatography consumables worldwide. It primarily focuses on expansion and new product launches as key growth strategies to broaden its global presence. Merck’s advantage lies in its historical relationships with European biopharmaceutical manufacturers and its broader portfolio across ion-exchange and mixed-mode chromatography. Merck KGaA's Life Science business, operating as MilliporeSigma in North America, commands a comprehensive downstream processing portfolio spanning chromatography resins (Eshmuno, Fractogel), membranes, buffers, columns, and integrated systems. The company's 2025 strategic acquisition of JSR Life Sciences' chromatography business—including Amsphere resins—signals deliberate portfolio expansion to strengthen monoclonal antibody purification capabilities and compete in the high-growth biologics segment. With nearly 26,000 employees globally and 55 manufacturing and testing sites, MilliporeSigma operates a distributed manufacturing footprint supporting pharmaceutical and biotech customers across North America, Europe, Asia-Pacific, and the Middle East.

Thermo Fisher Scientific, Inc. (US)

Thermo Fisher Scientific positions itself as a comprehensive bioprocessing solutions provider through its 2025 acquisition of Solventum's Purification & Filtration business, which generated significant annual revenue before integration. This strategic acquisition broadens Thermo Fisher's downstream portfolio by combining proprietary POROS affinity resins, ÄKTA systems, and a global infrastructure of 2,500+ colleagues across the Americas, Europe, Africa, the Middle East, and Asia Pacific.

Market Ranking

Danaher Corporation (US), through its subsidiaries Cytiva and Abcam, Merck KGaA (Germany), and Thermo Fisher Scientific, Inc. (US) are the leading companies in the global preparative and process chromatography market, each holding a strong and strategic position. Danaher, through Cytiva and Abcam, maintains the leading position, primarily due to its widely adopted consumable products. Thermo Fisher Scientific, Inc. (US) has consistently improved its single-use technology to meet demand for small-scale, modular manufacturing in cell and gene therapy. Merck is relatively more focused on consumable products to capture more recurring revenue.

Related Reports:

Preparative and Process Chromatography Market by Product [Preparative (Columns, System), Process (Resins, Services)], Application (Vaccines, Peptides & Oligonucleotides), End User (Food & Nutraceutical Companies, Others), Region - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com